Prime Minister Benjamin Netanyahu was diagnosed with prostate cancer and underwent radiation therapy without informing the public in real time, according to his annual medical report published Friday.
The report states that the treatment was “fully successful, with complete disappearance of the lesion, as confirmed by all radiological and laboratory tests.”
In a statement following the publication of the report, Netanyahu said he had requested a two-month delay in its release “so that it would not be published at the height of the war, in order not to allow the Iranian terrorist regime to spread further false propaganda against Israel.”
Haaretz PodcastMaking Israel’s case to ChatGPT and Grok: Hasbara meets AI in multi-million dollar PR push
play
Haaretz Podcast
Making Israel’s case to ChatGPT and Grok: Hasbara meets AI in multi-million dollar PR push
Volume: 0.5
X1
total– : –time0:00
fast forward15
play
rewind15
According to the report, the cancer was discovered during an MRI scan the prime minister underwent as part of routine follow-up after prostate surgery about a year and a half ago.
It further notes that “this was an early detection of a small lesion with no metastases, as all other tests have shown beyond any doubt.”
Related Articles
At Netanyahu’s age, 76, prostate cancer is very common and is not considered immediately dangerous when diagnosed at an early stage. In many older men, it develops so slowly that the likelihood of it causing death is significantly lower than the likelihood of dying from other age-related conditions.
According to Prof. Aron Popovtzer, director of the Sharett Oncology Institute at Hadassah Medical Center, Netanyahu was presented at diagnosis with two options: active surveillance or radiation therapy.
The prime minister, he said, chose to undergo radiation therapy about two and a half months ago. Subsequent evaluation, including imaging and blood tests, was then carried out.
“We can now say, based on the findings of these tests, that the disease has disappeared. There is no evidence of disease,” Popovtzer added. “The prime minister will continue routine standard follow-up as is customary.”